Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alpine Research Organization

Neither a doctor nor a teaching hospital

Research payments

$877,085

119 payments

Through program year 2025, Alpine Research Organization is reported as receiving $877,085 in research payments, across 119 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $115,600 25
2024 Research $31,989 14
2023 Research $331,587 28
2022 Research $226,835 29
2021 Research $124,363 14
2020 Research $19,475 4
2019 Research $27,237 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Indivior Inc. $384,592 60 payments
  2. Bausch & Lomb Americas Inc. $136,127 6 payments
  3. Pfizer Inc. $114,803 20 payments
  4. Aerie Pharmaceuticals, Inc. $109,700 10 payments
  5. Alcon Research LLC $63,434 6 payments
  6. Amgen Inc. $47,180 10 payments
  7. GlaxoSmithKline, LLC. $8,160 2 payments
  8. Lumos Diagnostics, Inc. $6,300 1 payment
  9. Novartis Pharmaceuticals Corporation $6,035 1 payment
  10. AbbVie, Inc. $754 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (Rbp-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-Risk Opioid Use $358,860 45 payments
  2. A Multi-Center, Double-Masked, Randomized, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Preservative-Free Formulation with Lumify 0.025% in Adult Subjects with Ocular Redness $136,127 6 payments
  3. An Interventional Efficacy and Safety Phase 3 Doubleblind 2Arm Study to Investigate Orally Administered Ibuzatrelvir Compared With Placebo in Nonhospitalized Symptomatic Adult and Adolescent Participants With Covid19 Who Are at High Risk of Progressing to Severe Illness $103,303 19 payments
  4. A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease $81,700 7 payments
  5. A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $52,174 5 payments
  6. Ophthalmic Assessments of Signs and Symptoms of Dry Eye in Patients Suffering from Self-Reported or Clinician-Diagnosed Dry Eye Disease $28,000 3 payments
  7. A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $25,732 15 payments
  8. Vesalius - CV $19,475 4 payments
  9. 20170625-Vesalius - CV $14,663 4 payments
  10. Vesalius-Cv $13,042 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record